PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents changing 32.15% while GNPX's remains stable. Warren Buffett would analyze the strategic implications of this divergence.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Higher Cash + Short-Term Investments Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Higher Total Current Assets Growth compared to GNPX's zero value, indicating better performance.
-2.88%
Both GNPX and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Both GNPX and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Higher Total Assets Growth compared to GNPX's zero value, indicating better performance.
63.16%
Higher Accounts Payable Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Higher Other Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
49.30%
Higher Total Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Higher Total Liabilities Growth compared to GNPX's zero value, indicating worse performance.
16.87%
Higher Common Stock (Book Value) Growth compared to GNPX's zero value, indicating worse performance.
-5.16%
Both GNPX and the company show zero Retained Earnings Growth.
-13.18%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Higher Total Stockholders' Equity Growth compared to GNPX's zero value, indicating better performance.
30.51%
Higher Liabilities + Equity Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Higher Net Debt Growth compared to GNPX's zero value, indicating worse performance.